Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease

详细信息    查看全文

• 作者：William P. Parker^a ; Brian J. Davis^b ; ^{davis.brian@mayo.edu} ; Sean S. Park^b ; Kenneth R. Olivier^b ; Richard Choo^b ; Mark A. Nathan^c ; Val J. Lowe^c ; Timothy J. Welch^c ; Jaden D. Evans^b ; William S. Harmsen^d ; Harras B. Zaid^a ; Ilya Sobol^a ; Daniel M. Moreira^a ; Rimki Haloi^a ; Matthew K. Tollefson^a ; Matthew T. Gettman^a ; Stephen A. Boorjian^a ; Lance A. Mynderse^a ; R. Jeffrey Karnes^a ; Eugene D. Kwon^a
• 关键词：Prostate Cancer ; Radiation Therapy ; Recurrence ; PET/CT ; Nomogram
• 刊名：European Urology
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：71
• 期：3
• 页码：340-348
• 全文大小：2144 K
• 卷排序：71

文摘

Management of recurrent prostate cancer (CaP) after radiotherapy (RT) is dependent on accurate localization of the site of recurrent disease.ObjectiveTo describe the anatomic patterns and clinical features associated with CaP recurrence following RT identified on advanced imaging.Design, setting, and participantsRetrospective review of 184 patients with a rising prostate-specific antigen (PSA) after RT for CaP.InterventionC-11 choline positron emission tomography/computed tomography (CholPET).Outcome measurements and statistical analysisRecurrence patterns were classified as pelvic soft tissue only (as a surrogate for potentially salvageable disease) versus any extrapelvic disease, and clinical features were compared between patterns. Multivariable logistic regression was used to generate a predictive nomogram for extrapelvic recurrence. Discrimination was assessed with a c-index.Results and limitationsRecurrence site was identified in 161 (87%) patients, with 95 (59%) sites histologically confirmed. Factors associated with the detection of recurrence included the difference between PSA nadir and PSA at CholPET (odds ratio: 1.30, p < 0.01) and National Comprehensive Cancer Network high-risk classification (odds ratio: 10.83, p = 0.03). One hundred (54.3%) patients recurred in the pelvic soft tissue only, while 61 (33%) had extrapelvic recurrence. Of 21 patients who underwent CholPET prior to meeting the Phoenix criteria of biochemical failure, 15 (71%) had recurrence identified on CholPET with 11 localized to the pelvis. On multivariable analysis, the difference between PSA nadir and PSA at CholPET, time from RT, and National Comprehensive Cancer Network risk group were predictive of recurrence outside of the pelvis, and a nomogram was generated with a c-index of 0.79.ConclusionsCholPET identified the site of recurrence in 87% of patients with a rising PSA after RT; most commonly within the pelvis in potentially salvageable locations. A predictive nomogram was generated, and pending external validation, this may aid in assessing the risk of disease beyond the pelvis. These findings underscore the importance of advanced imaging when considering management strategies for patients with a rising PSA following primary RT.Patient summaryWe identified anatomic patterns of recurrence in patients with a rising prostate-specific antigen after radiotherapy using C-11 choline positron emission tomography/computed tomography. Most recurrences were localized to the pelvis and we were able to generate a tool to aid in disease localization prior to evaluation with advanced imaging.